Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

The FDA completed a mid-cycle meeting for ulixacaltamide HCl and has identified no major safety or efficacy concerns to date. The agency does not plan to request an advisory committee meeting, with the PDUFA target set for January 29, 2027. Overall, the update is a modest positive on regulatory risk, though no final approval decision has been issued.

Analysis

The FDA completed a mid-cycle meeting for ulixacaltamide HCl and has identified no major safety or efficacy concerns to date. The agency does not plan to request an advisory committee meeting, with the PDUFA target set for January 29, 2027. Overall, the update is a modest positive on regulatory risk, though no final approval decision has been issued.